R&D Systems™ Recombinant Human VEGFR2/KDR Fc Chimera Protein

Description

Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity

The Recombinant Human VEGFR2/KDR Fc Chimera Protein is derived from NS0. The Recombinant Human VEGFR2/KDR Fc Chimera Protein has been validated for the following applications: Bioactivity.

Specifications

• Formulation: Lyophilized from a 0.2μm filtered solution in PBS with BSA as a carrier protein.
• Gene ID (Entrez): 3791
• Molecular Weight (g/mol): 110 kDa (monomer)
• Name: VEGFR2/KDR/Flk-1
• Quantity: 50 μg
• Source: Mouse myeloma cell line,NS0-derived human VEGFR2/KDR/Flk-1 protein, (N-terminus) Human VEGFR2 (Ala20-Glu764) Accession &Num; AAC16450 IEGRMD Human IgG1 (Pro100-Lys330) 6-His tag (C-terminus)
• Storage Requirements: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution.
• Structural Form: Disulfide-linked homodimer
• Gene Alias: CD309, CD309 antigen, EC 2.7.10, EC 2.7.10.1, Fetal liver kinase 1, fetal liver kinase-1, Flk1, Flk-1, FLK1tyrosine kinase growth factor receptor, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), KRD1, Ly73, Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, vascular endothelial growth factor receptor 2, VEGF R2, VEGFR, VEGFR2, VEGFR-2
• Conjugate: Unconjugated
• Recombinant: Recombinant
• Purity or Quality Grade: 90%, by SDS-PAGE under reducing conditions and visualized by silver stain.